Sirona Biochem Announces Positive Results With SBM-TFC-837 for Anti-Aging And Regenerative Medicine

Vancouver, British Columbia – March 24, 2015 - Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) is pleased to announce that its French partner, Biogalenys, observed positive effects of Sirona’s glycoprotein SBM-TFC-837 on human fibroblasts in preliminary, in vitro, studies in response to the stressed condition of ultraviolet (UV) radiation. The results of these studies demonstrated a dramatic increase in percent cell viability over time with SBM-TFC-837, which suggests our glycoprotein plays an important role in protection against UV induced cell death.

“These results are tremendously exciting and further add to our previously reported results which demonstrated that our glycoproteins were protective against extreme conditions,” said Attila Hajdu, Chief Business Development officer of Sirona Biochem. “We have added this new data to our existing patent and have recently generated significant interest from major pharmaceutical companies that recognize the value that our fluorination platform technology provides.” Further studies are ongoing and will continue to assess cell stressors and viability. The compounds may have applications in:

• Anti-aging cosmetic product since 80% of visible aging is directly related to cell death

• Cryopreservation

• Regenerative and protective cosmetic or pharmaceutical product for healing, wound care, hypothermic protection, sunscreen, post burn / radiotherapy

• Regenerative and protective pharmaceutical product against stress response in renal reperfusion and the improvement of engraftment

• Pharmaceutical product used in organ transplantation solution (for example Wisconsin solution)

• Regenerative and preservative product for preservation of stem cells, ß-islet cells, red blood cells, adipocytes and platelets as well as tissues including reconstituted human epithelial cells, skin explants and cornea

• Preservative for vaccines

The global anti-aging market is forecast to reach up to $345.8 billion US in 2018 from $249.3 billion in 2012. The related market for regenerative medicine, which aims to restore functional ability to tissues and organs, is set to hit $67.6 billion US in 2020.

The anti-aging project is supported by Bpifrance and the region Haute Normandie.

For more information regarding this press release, please contact:
Christopher Hopton, CFO
Sirona Biochem Corp.
Phone: 1.604.282.6064
Email: chopton@sironabiochem.com

Help employers find you! Check out all the jobs and post your resume.

Back to news